Iron Deficiency Anemia Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy, Red Blood Cell Transfusion), By End User (Hospitals, Clinics, and Home Healthcare), By Region and Competition, 2020-2030F

Market Overview

The Global Iron Deficiency Anemia Therapy Market, valued at USD 5.49 Billion in 2024, is projected to experience a CAGR of 6.70% to reach USD 8.10 Billion by 2030. Iron Deficiency Anemia (IDA) Therapy involves pharmaceutical interventions, primarily oral and intravenous iron supplements, designed to replenish depleted iron stores, thereby enabling adequate hemoglobin synthesis and alleviating symptoms associated with iron deficiency. The global market's expansion is significantly propelled by the increasing worldwide prevalence of iron deficiency anemia, heightened public and medical awareness concerning early diagnosis and effective management, and advancements in therapeutic formulations. According to the World Health Organization (WHO), in 2023, 30.7% of women aged 15-49 years suffered from anemia, with iron deficiency being its most common cause, underscoring a substantial patient demographic.

A notable challenge impeding market growth is the considerable cost associated with advanced intravenous iron therapies, alongside the prevalent gastrointestinal side effects linked to various oral iron supplements, which can compromise patient adherence to prescribed treatment protocols.

Key Market Drivers

The rising prevalence of iron deficiency anemia fundamentally drives market expansion, creating a substantial global demand for effective therapeutic interventions. This widespread nutritional deficiency necessitates consistent, accessible treatment, directly propelling the growth of pharmaceutical and supplementary solutions. For instance, according to the World Health Organization, in February 2025, an estimated 269 million children aged 6-59 months worldwide were affected by anemia. This large patient demographic ensures continuous requirement for diagnosis and subsequent treatment, underpinning the market’s sustained growth.

The growing incidence of chronic diseases significantly contributes to the iron deficiency anemia therapy market by generating a complex patient subgroup with persistent iron management needs. Conditions like chronic kidney disease, inflammatory bowel disease, and various cancers often induce secondary anemia, frequently difficult to address with standard oral iron due to inflammation induced malabsorption or intolerance. According to PubMed Central, in May 2025, global chronic kidney disease related anemia cases reached over 63 million in 2021, marking a considerable increase. These comorbidities necessitate advanced, often intravenous, iron formulations for effective repletion, stimulating innovation and adoption of specialized therapies. The market's responsiveness to patient requirements is further demonstrated by the broader geographical reach of key products; according to BioSpace, in July 2024, Ferinject ferric carboxymaltose, a prominent intravenous iron therapy, held marketing authorization in 87 countries.

Download Free Sample Report

Key Market Challenges

The considerable cost associated with advanced intravenous iron therapies presents a significant challenging factor, directly impeding the growth of the Global Iron Deficiency Anemia Therapy Market. This high cost often results in restrictive reimbursement policies from payers, who may prioritize less expensive, older-generation intravenous iron formulations through mechanisms such as step therapy requirements. Such policies compel patients to first attempt therapies that may be less effective or require more frequent administrations.

This practice directly hampers market expansion for advanced therapies by limiting initial access and adoption. It can lead to suboptimal patient outcomes due to delayed access to more efficacious treatments or increased patient non-adherence. According to research published in *The American Journal of Managed Care* in 2023, patients on older-generation intravenous iron products exhibited a 55% discordance rate to their prescribed therapy, compared to only 16% for those receiving newer-generation products. This substantial difference in adherence, often influenced by the upfront cost and subsequent payer mandates, directly hinders the market by delaying or preventing the widespread utilization of advanced iron therapies.

Key Market Trends

The emergence of nanomedicine in iron formulations represents a significant advancement, addressing challenges associated with conventional iron therapies such as bioavailability and side effects. These novel formulations, designed at the nanoscale, offer improved absorption kinetics and reduced gastrointestinal distress, enhancing patient adherence and therapeutic outcomes. For instance, in February 2023, the IHAT-GUT trial published in *EClinicalMedicine* demonstrated that a novel nano-iron supplement, iron hydroxide adipate tartrate (IHAT), showed non-inferiority compared to standard ferrous sulfate for iron deficiency correction and hemoglobin response in children aged 6-35 months, warranting further Phase III trials. The European Hematology Association (EHA) also dedicated two oral sessions to iron metabolism and altered iron homeostasis during its 2023 Congress, reflecting the growing scientific and industrial interest in innovative iron therapies. This focus on nanotechnology is paving the way for more targeted and efficient treatments, driving market growth through product innovation.

The shift towards home healthcare and community clinic treatment settings is fundamentally reshaping how iron deficiency anemia therapies are delivered, moving away from traditional hospital-centric models. This trend is driven by a desire for increased patient convenience, reduced healthcare costs, and improved accessibility, particularly for chronic conditions requiring long-term management. Home infusion therapy providers are expanding their services, with the 2024 National Home Infusion Association (NHIA) Conference reporting a record high attendance of over 1,600 home infusion and alternate site professionals, alongside more than 135 companies showcasing products and services. Similarly, specialized collaborative clinics, such as one established within an advanced heart failure service, have proven effective in optimizing intravenous iron therapy for iron-deficient patients, as noted in the *American Journal of Health-System Pharmacy* in September 2023. This decentralization of care expands the market by reaching a broader patient demographic and improving continuity of treatment.

Segmental Insights

The Global Iron Deficiency Anemia Therapy Market identifies oral iron therapy as its fastest-growing segment, primarily driven by its inherent advantages. This segment experiences rapid growth due to its cost-effectiveness, straightforward administration, and high patient preference for non-invasive treatment modalities. Furthermore, major health bodies, such as the World Health Organization, consistently recommend oral iron as the primary therapeutic approach for managing most cases of iron deficiency anemia, thereby solidifying its market position and fostering sustained demand globally.

Regional Insights

North America is a key region in the global iron deficiency anemia therapy market, primarily driven by its advanced healthcare infrastructure and significant investments in research and development. The region benefits from a high prevalence of the condition, coupled with robust reimbursement policies that facilitate access to various treatment options. The presence of major pharmaceutical companies actively developing and launching new iron formulations, including both oral and intravenous therapies, further strengthens its market position. Additionally, favorable government support, including funding for research and initiatives by regulatory bodies such as the U. S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) for screening programs and nutritional guidance, contributes to market expansion and early diagnosis.

Recent Developments

• In August 2025, Viatris received FDA approval for the first generic iron sucrose injection in the United States, securing 180-day market exclusivity. This regulatory achievement signified an expansion of treatment options for patients with iron deficiency anemia, especially those with chronic kidney disease who require intravenous iron therapy. The availability of this generic product was anticipated to increase competition among suppliers and potentially enhance access to more affordable intravenous iron treatments, thereby contributing to the evolving landscape of iron deficiency anemia therapy.

• In August 2024, Shield Therapeutics announced that its product, ACCRUFeR (ferric maltol), received approval from Health Canada. This approval designated ACCRUFeR as a prescription drug for treating iron deficiency anemia in adults. This development was a significant achievement for the company, establishing ACCRUFeR as the exclusive oral iron therapy available by prescription in Canada. Following this regulatory milestone, Shield Therapeutics’ partner, Kye Pharmaceuticals, prepared for the subsequent market launch in Canada, with Shield overseeing all manufacturing and supply operations for the product.

• In April 2024, Keylika, a biopharma startup, was actively developing NistuFe, a novel prescription resorbable buccal patch intended for the treatment of iron deficiency anemia. This breakthrough research aimed to introduce a new drug delivery system that could circumvent common gastrointestinal side effects associated with traditional oral iron supplements. The company's proprietary iron chemical entity, administered via the buccal patch, also sought to provide superior absorption and facilitate convenient self-administration. Keylika's efforts were focused on enhancing patient experience and expanding access to effective treatments within the global iron deficiency anemia therapy market.

• In March 2024, Akebia Therapeutics, Inc. announced that the FDA granted approval for its medication, Vafseo (vadadustat), in tablet form. This approval was specifically for the treatment of anemia in adult patients suffering from chronic kidney disease (CKD), encompassing both dialysis-dependent and non-dialysis-dependent individuals. The introduction of Vafseo represented a notable advancement in therapeutic options within the global iron deficiency anemia therapy market, particularly addressing the complex needs of patients whose anemia is linked to chronic kidney disease.

Key Market Players

• Daiichi Sankyo Company
• Novartis AG
• Rockwell Medical Inc
• Iron4u Aps
• AbbVie Inc
• Sanofi
• Disc Medicine Inc
• Pfizer Inc
• Akebia Therapeutics
• Keros Therapeutics Inc

Report Scope:

In this report, the Global Iron Deficiency Anemia Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Iron Deficiency Anemia Therapy Market, By Therapy Type:

o   Oral Iron Therapy

o   Parenteral Iron Therapy

o   Red Blood Cell Transfusion

• Iron Deficiency Anemia Therapy Market, By End User:

o   Hospitals

o   Clinics

o   Home Healthcare

• Iron Deficiency Anemia Therapy Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Iron Deficiency Anemia Therapy Market.

Available Customizations:

Global Iron Deficiency Anemia Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Iron Deficiency Anemia Therapy Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]